2021 Alzheimer's disease facts and figures
- PMID: 33756057
- DOI: 10.1002/alz.12328
2021 Alzheimer's disease facts and figures
Abstract
This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on caregivers and society. The Special Report discusses the challenges of providing equitable health care for people with dementia in the United States. An estimated 6.2 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available, making Alzheimer's the sixth-leading cause of death in the United States and the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. This trajectory of deaths from AD was likely exacerbated in 2020 by the COVID-19 pandemic. More than 11 million family members and other unpaid caregivers provided an estimated 15.3 billion hours of care to people with Alzheimer's or other dementias in 2020. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $256.7 billion in 2020. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are more than three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 23 times as great. Total payments in 2021 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $355 billion. Despite years of efforts to make health care more equitable in the United States, racial and ethnic disparities remain - both in terms of health disparities, which involve differences in the burden of illness, and health care disparities, which involve differences in the ability to use health care services. Blacks, Hispanics, Asian Americans and Native Americans continue to have a higher burden of illness and lower access to health care compared with Whites. Such disparities, which have become more apparent during COVID-19, extend to dementia care. Surveys commissioned by the Alzheimer's Association recently shed new light on the role of discrimination in dementia care, the varying levels of trust between racial and ethnic groups in medical research, and the differences between groups in their levels of concern about and awareness of Alzheimer's disease. These findings emphasize the need to increase racial and ethnic diversity in both the dementia care workforce and in Alzheimer's clinical trials.
Keywords: Alzheimer's dementia; Alzheimer's disease; Biomarkers; COVID-19; Caregivers; Dementia; Diagnostic criteria; Discrimination; Diversity; Equity; Ethnicity; Family caregiver; Health care costs; Health care disparities; Health care expenditures; Health care professional; Health disparities; Implicit bias; Incidence; Long-term care costs; Medicaid spending; Medicare spending; Morbidity; Mortality; Prevalence; Race; Risk factors; Spouse caregiver.
© 2021 the Alzheimer's Association.
Similar articles
-
2023 Alzheimer's disease facts and figures.Alzheimers Dement. 2023 Apr;19(4):1598-1695. doi: 10.1002/alz.13016. Epub 2023 Mar 14. Alzheimers Dement. 2023. PMID: 36918389
-
2024 Alzheimer's disease facts and figures.Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. Alzheimers Dement. 2024. PMID: 38689398 Free PMC article.
-
2022 Alzheimer's disease facts and figures.Alzheimers Dement. 2022 Apr;18(4):700-789. doi: 10.1002/alz.12638. Epub 2022 Mar 14. Alzheimers Dement. 2022. PMID: 35289055
-
Alzheimer's disease and its related dementias in US Native Americans: A major public health concern.Ageing Res Rev. 2023 Sep;90:102027. doi: 10.1016/j.arr.2023.102027. Epub 2023 Aug 5. Ageing Res Rev. 2023. PMID: 37544432 Free PMC article. Review.
-
Impact of dementia: Health disparities, population trends, care interventions, and economic costs.J Am Geriatr Soc. 2021 Jul;69(7):1774-1783. doi: 10.1111/jgs.17345. J Am Geriatr Soc. 2021. PMID: 34245588 Free PMC article. Review.
Cited by
-
Recent developments in the probiotics as live biotherapeutic products (LBPs) as modulators of gut brain axis related neurological conditions.J Transl Med. 2022 Oct 8;20(1):460. doi: 10.1186/s12967-022-03609-y. J Transl Med. 2022. PMID: 36209124 Free PMC article. Review.
-
The effect of consuming nuts on cognitive function: a systematic review and meta-analysis of randomized clinical trials.Front Nutr. 2024 Sep 4;11:1463801. doi: 10.3389/fnut.2024.1463801. eCollection 2024. Front Nutr. 2024. PMID: 39296505 Free PMC article.
-
Association of late-life body mass index with the risk of Alzheimer disease: a 10-year nationwide population-based cohort study.Sci Rep. 2022 Sep 12;12(1):15298. doi: 10.1038/s41598-022-19696-2. Sci Rep. 2022. PMID: 36097042 Free PMC article.
-
How donanemab data address the coverage with evidence development questions.Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7. Alzheimers Dement. 2024. PMID: 38323738 Free PMC article. Review.
-
A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.J Alzheimers Dis. 2023;94(s1):S227-S239. doi: 10.3233/JAD-220651. J Alzheimers Dis. 2023. PMID: 36336932 Free PMC article. Review.
References
REFERENCES
-
- Quiroz YT, Zetterberg H, Reiman EM, et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross-sectional and longitudinal cohort study. Lancet Neuro 2020;19(6):513-521.
-
- Barthelemy N, Joseph-Mathurin N, Gordon BA, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med 2020;26:398-407.
-
- Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12(4):357-367.
-
- Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol 2012;11(2):1048-1056.
-
- Jack CR, Lowe VJ, Weigand SD, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical